Tonix Pharma (TNXP) has shared an update.
Tonix Pharmaceuticals Holding Corp. has refreshed its investor presentation, including updates on its CD45 product candidate. These presentations, soon to be available on the company’s website, may offer previously undisclosed information. Although important for stakeholders, the data within these presentations is not considered legally filed under U.S. securities laws but is referenced for informational purposes in recent corporate filings.
For an in-depth examination of TNXP stock, go to TipRanks’ Stock Analysis page.
